Evidence & regulatory context
- Mechanism
- Polyclonal antibody neutralising the extracellular matrix glycoprotein tenascin-R; research reagent, no ChEMBL drug entity. No ClinicalTrials.gov entries for tenascin-R antibodies (registered tenascin programmes target tenascin-C in oncology).
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Tenascin-R; TN-R; Restrictin; Janusin
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryHemisection / partialSprague-DawleyFemaleLocal administration into the lesion site
Model: Spinal cord dorsal hemisection transecting the corticospinal tract
The tenascin-R polyclonal antibody promoted neurite outgrowth and sprouting on inhibitory tenascin-R substrate in vitro, and after local administration into dorsal hemisection lesions significantly decreased RhoA activation and improved functional recovery from corticospinal tract transection.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.